Navigation Links
Halocarbon Announces Licensing Agreement with IBM

Halocarbon has long produced hexafluoroisopropanol (HFIP) and has now entered into a licensing agreement with IBM to access IBM's industry-leading portfolio of patents related to hexafluoroisopropanol-based photoresists for semiconductor manufacturing.

River Edge, NJ (PRWEB) -- Halocarbon Products Corporation (, a leading worldwide producer of specialty fluorochemicals, has entered into a licensing agreement with IBM to access IBM's industry-leading portfolio of patents related to hexafluoroisopropanol-based photoresists for semiconductor manufacturing.

"Halocarbon has long produced hexafluoroisopropanol (HFIP) as a key component in the manufacture of the anesthetic sevoflurane," said Halocarbon CEO Peter Murin. "With this agreement, we can partner our fluorochemicals development and manufacturing expertise with IBM's leadership in developing advanced electronic materials such as photoresists."

"This agreement will allow us to leverage our HFIP business and provide reliable, regular, cost-effective, US-based production of advanced photoresist compounds," added Murin.

About Halocarbon
With headquarters in River Edge, New Jersey, and a state-of-the-art manufacturing plant in North Augusta, South Carolina, USA, Halocarbon is one of the world's leading producers of specialty fluorochemicals. Halocarbon products include inert lubricants, aliphatic fluorochemicals for pharmaceutical and agricultural chemical manufacturing, inhalation anesthetics and other specialty products. For more information, please contact the company at +1-201-262-8899 or at

# # #

Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. PDL BioPharma Announces Conversion Rate Adjustment for Its 2.00% Convertible Senior Notes Due February 15, 2012
2. AMDL Inc. Announces Stockholder Approval of Name Change and Issuance of a New Trading Symbol on the NYSE Alternext US
3. LCA-Vision Announces CEO Resignation
4. Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers
5. Rigel Announces Pricing of Public Offering of 13,000,000 Shares of Common Stock
6. InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis
7. Aethlon Medical, Inc. Announces Annual Meeting Results
8. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
9. Martek Announces Addition to Its Board of Directors
10. Pervasis Therapeutics Announces $17 Million in Financing and New Board Member
11. BVGH Announces New Board Chair
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... New York on Wednesday, December 2 at ... , president and CEO, will provide a corporate overview. ... at 1:00 p.m. ET/10:00 a.m. PT . ... will provide a corporate overview. --> th Annual ...
(Date:11/24/2015)... 24, 2015  Clintrax Global, Inc., a worldwide provider of clinical ... today announced that the company has set a new quarterly earnings ... on quarter growth posted for Q3 of 2014 to Q3 of ... Mexico , with the establishment of an ... --> United Kingdom and Mexico ...
(Date:11/24/2015)... , November 24, 2015 ... recent market research report released by Transparency Market Research, ... expand at a CAGR of 17.5% during the period ... Testing Market - Global Industry Analysis, Size, Volume, Share, ... global non-invasive prenatal testing market to reach a valuation ...
(Date:11/24/2015)... ... 2015 , ... InSphero AG, the leading supplier of easy-to-use solutions for production, ... to serve as Chief Operating Officer. , Having joined InSphero in November ... and was promoted to Head of InSphero Diagnostics in 2014. There she has ...
Breaking Biology Technology:
(Date:11/17/2015)... , November 17, 2015 ... au 19 novembre  2015.  --> Paris ... --> DERMALOG, le leader de l,innovation biométrique, ... la fois passeports et empreintes sur la même surface ... les passeports et l,autre pour les empreintes digitales. Désormais, ...
(Date:11/12/2015)... BOSTON , Nov. 12, 2015  A golden ... for Duchenne muscular dystrophy (DMD) has provided a new ... Boston Children,s Hospital, the Broad Institute of MIT and ... Brazil . Cell, ... some dogs "escape" the disease,s effects. The Boston Children,s ...
(Date:11/10/2015)...  In this report, the biomarkers market ... type, application, disease indication, and geography. The ... consumables, services, software. The type segments included ... biomarkers, and validation biomarkers. The applications segments ... drug discovery and development, personalized medicine, disease ...
Breaking Biology News(10 mins):